2018 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2020 (v1)Publication
Introduction: Biologics have revolutionized the therapy of moderate-to-severe plaque psoriasis. Yet, despite their greater efficacy over conventional systemic therapies their high cost has represented a burden for healthcare systems, which limited their use. More recently, the availability of several biosimilars at low cost is changing the...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
BackgroundGuselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. ObjectivesWe conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of...
Uploaded on: February 14, 2024 -
2022 (v1)Publication
A nationwide survey was conducted in adult patients with psoriasis (PsO) across Italy to obtain their real-world perspective of the impact of PsO on their wellbeing. Patients completed a 26-question survey (based on the patient benefit index; PBI, The Dermatology Life Quality Index; DLQI and the World Health Organization-five; WHO-5 wellbeing...
Uploaded on: February 6, 2024